Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavyret +/- Ribavirin in NS5A+Sofosbuvir Experienced GT1 HCV
NCT03092375Phase 3Completed
- Sponsor
- University of Florida
- Start
- Apr 2017
- Primary completion
- Dec 2018
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of glecaprevir in chronic hepatitis C virus infection (4 arms), sponsored by University of Florida. Primary endpoints: Sustained Virologic Response at 12 Weeks and Tolerability of G/P +/- RBV up to 16 weeks. Started Apr 2017; status: completed.
02
Drugs
glecaprevir
03
Conditions
chronic hepatitis C virus infection
Beyond the preview
Go deeper on NCT03092375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03092375.